Deals & IPOs

Petauri Buys Emotive to Expand Global Medical Communications Arm

Petauri acquires medical communications agency Emotive, folding it into Petauri Advance as the Oak Hill-backed platform pushes past 600 staff and $250M in committed equity.

By Nathan Brooks

3 min read

Petauri: Emotive Acquisition Expands Global Medical Communications And Pharmaceutical Services
Petauri: Emotive Acquisition Expands Global Medical Communications And Pharmaceutical Servicesjarmoluk / pixabay

What's News

  • Petauri acquired Emotive, founded in 2013, and integrated it into its Petauri Advance medical communications collective.
  • Oak Hill Capital has committed over $250 million in equity to Petauri's platform through its sixth fund.
  • Petauri employs more than 600 professionals globally across six operating divisions.
  • Emotive founder and CEO Chris Edmonds becomes Executive Advisor at Petauri post-deal.
  • Petauri Advance already includes DRIVE, PROPEL, MOMENTUM, BluPrint Oncology, Verascity Science and Cogency.

Petauri has acquired Emotive, a global medical communications agency, and folded it into Petauri Advance — the medical communications collective at the heart of a platform built on more than $250 million in committed equity from Oak Hill Capital.

The deal, announced without a disclosed price, expands Petauri's international capacity in scientific, strategic and creative services for pharmaceutical companies. Emotive, founded in 2013, brings deep expertise across neuroscience, immunology, oncology and rare diseases — therapeutic categories where the science is hardest to explain and the stakes for clear communication are highest.

What does this change for pharma clients?

Practically, it widens the bench. Emotive joins an existing roster of Petauri Advance agencies that includes DRIVE, PROPEL, MOMENTUM, BluPrint Oncology, Verascity Science and Cogency. Clients now get access to a coordinated international platform covering strategic planning, medical insights, disease education, promotional communications, scientific publications and professional medical meetings — including support for congresses and symposia where new research gets debated.

That matters because healthcare professionals, payers and other stakeholders need solid clinical evidence to evaluate new medicines. Medical communications agencies translate that evidence into formats and channels that actually reach the people shaping patient care.

Petauri CEO Dan Renick framed the logic in terms of therapeutic complexity: "As therapies become increasingly complex, our clients need partners that can not only understand the science behind them but translate it for the people who ultimately shape patient care. Emotive does just that by bridging scientific precision and industry-recognized creativity to inspire change and help lifesaving treatments reach those who need them most."

Who is Petauri, and why the momentum?

Petauri is young. CEO Dan Renick established the company in 2023 in partnership with Oak Hill Capital, which has committed the $250 million-plus in equity through its sixth fund. In roughly two years, the firm has launched and acquired multiple businesses and now runs six operating divisions: Petauri Advance, Petauri Advisors, Petauri Evidence, Petauri Kinect, Petauri MAx and Artia Solutions.

The organization employs more than 600 professionals globally and serves hundreds of pharmaceutical and life sciences companies with communicating the clinical, economic and broader value of medical treatments. That scale puts Petauri among the consolidators racing to build one-stop shops for pharma commercialization support.

Lisa Hefler, Group President of Petauri Advance, pointed to the fit between the teams. "The strength of this combination lies in the complementary expertise of our teams, our shared core values, and the aligned vision for the future of healthcare communications," she said. "Together, our teams bring specialized knowledge across geographies, therapeutic areas, and disciplines to deliver more connected, impactful solutions earlier in the asset life cycle, ultimately helping to improve patient outcomes."

Leadership continuity

Chris Edmonds, Founder and CEO of Emotive, stays on as Executive Advisor within Petauri. His continued involvement is intended to smooth integration and preserve client relationships — usually the fragile point in agency roll-ups.

Edmonds cast the deal as scale without dilution: "Joining Petauri represents an exciting next chapter for Emotive. Emotive was built to turn complex science into communications that inspire meaningful change. Together with Petauri, we can build on that ambition, expanding what we can bring to clients while preserving the partnership they value."

The forward case is straightforward: Petauri expects the combination to let it support clients earlier in therapy development and throughout commercialization. For a two-year-old platform with Oak Hill's capital behind it, Emotive is unlikely to be the last acquisition.

Source: pulse2.com

Share this article:

More from Nathan Brooks

Nathan Brooks

Show full bio

News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.

2,426 articles

Related articles

« Previous articleNext article »